Ginkgo Bioworks Holdings (DNA) Total Current Liabilities (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Total Current Liabilities for 7 consecutive years, with $72.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 24.79% year-over-year to $72.7 million; the trailing twelve-month figure through Jun 2026 stood at $72.7 million (down 24.79% YoY), and the FY2025 full-year result was $96.0 million, down 10.53% from the prior year.
• Total Current Liabilities slipped to $72.7 million in Q2 2026 per DNA's latest filing, from $79.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $191.7 million in Q1 2023 and bottomed at $72.7 million in Q2 2026.
• Historically, Total Current Liabilities has averaged $134.0 million across 5 years, with a median of $129.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 11100.25% in 2022, then plunged 41.79% in 2025.
• Over 5 years, Total Current Liabilities stood at $173.0 million in 2022, then dropped by 5.26% to $163.9 million in 2023, then sank by 34.54% to $107.3 million in 2024, then slipped by 10.53% to $96.0 million in 2025, then retreated by 24.21% to $72.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $72.7 million, $79.6 million, and $96.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.